Education
About Us
Working with TipRanks
Follow Us
Sinopharm Group Co Ltd Class H (SHTDF)
OTHER OTC:SHTDF
SHTDF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.97 - $3.22
Previous CloseN/A
Volume100.00K
Average Volume (3M)194.00
Market Cap
$7.17B
Enterprise ValueN/A
Total Cash (Recent Filing)¥63.81B
Total Debt (Recent Filing)¥73.78B
Price to Earnings (P/E)6.8
Beta0.76
Next Earnings
Apr 24, 2025EPS Estimate
0.2Next Dividend Ex-Date
Jun 16, 2025Dividend Yield5.69%
Share Statistics
EPS (TTM)0.31
Shares Outstanding1,341,810,800
10 Day Avg. Volume384
30 Day Avg. Volume194
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.14
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.02Price Target Upside40.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Sinopharm Group Co News
PremiumCompany Announcements
Sinopharm Group Announces Board Meeting to Review Q1 2025 Results
PremiumCompany Announcements
Sinopharm Accord Reports Significant Profit Decline in 2024
PremiumCompany Announcements
Sinopharm Group’s 2024 Transformation and Innovation Drive
PremiumCompany Announcements
Sinopharm Group Announces Final Dividend for 2024
PremiumCompany Announcements
Sinopharm Group Reports Challenging 2024 Financial Results
PremiumCompany Announcements
Sinopharm’s CNMDC Reports Decline in 2024 Financial PerformancePremiumCompany Announcements
Sinopharm Reports Mixed Financial Results for 2024PremiumCompany Announcements
Sinopharm Accord Reports Significant Profit Decline in 2024---
Bulls Say, Bears Say
Bulls Say
Market PositionContinuous market share gains from industry consolidation could make Sinopharm remain the largest drug distributor in China and expand its market share significantly.
Operational EfficiencyA new policy allows medical institutes to apply for funds for payment to suppliers in advance, speeding up pharm distributor payments.
Bears Say
Earnings Performance1H24 earnings dropped by 10% y/y, below expectation.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
13.63% Mutual Funds
― Other Institutional Investors
77.25% Public Companies and
Individual Investors
SHTDF FAQ
What was Sinopharm Group Co Ltd Class H’s price range in the past 12 months?
Sinopharm Group Co Ltd Class H lowest stock price was $1.97 and its highest was $3.22 in the past 12 months.
What is Sinopharm Group Co Ltd Class H’s market cap?
Sinopharm Group Co Ltd Class H’s market cap is $7.17B.
When is Sinopharm Group Co Ltd Class H’s upcoming earnings report date?
Sinopharm Group Co Ltd Class H’s upcoming earnings report date is Apr 24, 2025 which is in 10 days.
How were Sinopharm Group Co Ltd Class H’s earnings last quarter?
Sinopharm Group Co Ltd Class H released its earnings results on Mar 23, 2025. The company reported $0.077 earnings per share for the quarter, missing the consensus estimate of $0.192 by -$0.115.
Is Sinopharm Group Co Ltd Class H overvalued?
According to Wall Street analysts Sinopharm Group Co Ltd Class H’s price is currently Undervalued.
Does Sinopharm Group Co Ltd Class H pay dividends?
Sinopharm Group Co Ltd Class H pays a Annually dividend of $0.094 which represents an annual dividend yield of 5.69%. See more information on Sinopharm Group Co Ltd Class H dividends here
What is Sinopharm Group Co Ltd Class H’s EPS estimate?
Sinopharm Group Co Ltd Class H’s EPS estimate is 0.2.
How many shares outstanding does Sinopharm Group Co Ltd Class H have?
Sinopharm Group Co Ltd Class H has 1,341,810,800 shares outstanding.
What happened to Sinopharm Group Co Ltd Class H’s price movement after its last earnings report?
Sinopharm Group Co Ltd Class H reported an EPS of $0.077 in its last earnings report, missing expectations of $0.192. Following the earnings report the stock price went down -4.348%.
Which hedge fund is a major shareholder of Sinopharm Group Co Ltd Class H?
Currently, no hedge funds are holding shares in SHTDF
---
Sinopharm Group Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.02 (40.47% Upside)
$3.02 (40.47% Upside)
Blogger Sentiment
Neutral
SHTDF Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.85%
12-Months-Change
Fundamentals
Return on Equity
9.19%
Trailing 12-Months
Asset Growth
-0.45%
Trailing 12-Months
Company Description
Sinopharm Group Co Ltd Class H
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
---
SHTDF Stock 12 Month Forecast
Average Price Target
$3.02
▲(40.47% Upside)
Technical Analysis
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
CSPC Pharmaceutical Group
―
China Medical System Holdings
―
China Resources Pharmaceutical Group Ltd.
―
Best Analysts Covering SHTDF
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-15.94%
reiterated a buy rating 21 days ago
Copying Jialin Zhang's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -15.94% per trade.
---